IRONWOOD PHARMACEUTICALS INC

Silver Ronald’s Rule 10b5‑1 sale of 127,890 Ironwood shares is a planned exit, not a warning, and other insiders’ buying keeps confidence high.

Insider buying spikes at Ironwood Pharmaceuticals—executives purchase 300,000+ shares after debt clearance, signaling confidence and potential growth ahead.

Insider buying fuels optimism for Ironwood Pharma: executives pile into Class A shares, signaling confidence in the pipeline and long‑term upside.

Insider buying dominates Ironwood: Ronald’s modest sell under a Rule 10b‑5 plan contrasts with Director Denner’s aggressive accumulation, signaling bullish confidence amid strong earnings and a $4.30 price well below year highs.